BETA-ADRENOBLOCKER THERAPY IN ARTERIAL HYPERTENSION, METABOLIC DISTURBANCES, AND TYPE 2 DIABETES MELLITUS

The paper presents modern views on beta-blocker therapy in clinical practice. The beta-blocker group is heterogeneous in terms of clinical usage. The recent critical comments by some researchers on beta-blocker therapy should not misguide the practitioners, who always need to ask themselves the key question: what specific beta-blockers are discussed. In fact, some beta-blockers, especially non-selective ones, could demonstrate negative effects and are contraindicated in specific clinical situations. The problem of negative metabolic influences is particularly important for the patients with metabolic syndrome and Type 2 diabetes mellitus (DM-2). However, modern super-selective beta-blockers did not have these negative effects and could be widely used in clinical practice, even in patients with metabolic syndrome and DM-2.